Get all your news in one place.
100's of premium titles.
One app.
Start reading
The Guardian - US
The Guardian - US
Politics
Hannah Harris Green in Rio de Janeiro

HIV prevention drug could reduce cases globally but USAID cuts prevent access, say experts

People hold signs on stage
People protest against funding cuts and drug patents during the 26th International Aids Conference in Rio de Janeiro on Monday. Photograph: Pablo Porciúncula/AFP via Getty Images

New innovations in HIV prevention could dramatically reduce the number of new HIV cases around the globe, but US foreign aid cuts will mean that those that most need the new medication will be unable to access it, according to experts at the Aids 2026 Conference in Rio de Janeiro, Brazil.

One year ago, the World Health Organization recommended that governments around the world prioritize expanded access to lenacapavir, an injectable version of the HIV prevention medication PrEP that requires only two injections annually. PrEP, which also comes in the form of daily oral medications and bimonthly injections, is 99% effective in preventing sexually transmitted HIV for people who take it consistently.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.